Cheryl Corcoran, M.D.
Assistant Professor of Clinical Psychiatry
Dr. Corcoran has expertise in schizophrenia, specifically its early stages.
Her research focus has been to identify biomarkers of risk and illness progression in schizophrenia: in collaboration, she has identified increased limbic activation, cognitive disorganization, social cognitive deficits, and sensory processing abnormalities as risk biomarkers for schizophrenia. She is now utilizing the tools of cognitive neuroscience, including neural imaging, EEG and brain stimulation, to more fully characterize these deficits, such that early intervention strategies can be developed and implemented. This includes a focus on negative symptoms such as low motivation, which accounts for the main functional impairment of schizophrenia, apart from psychotic symptoms. Dr. Corcoran has also studied the role of environment in schizophrenia risk and onset, including stress and cannabis use, as well as stigma and recovery related to schizophrenia.
Undergraduate: Harvard University, A.B. in Biology, 1985
Graduate: Mailman School of Public Health, M.S. in Biostatistics, 2005
Medical School: Harvard Medical School, M.D., 1990
Internship: The Cambridge Hospital, Transitional, 1990 - 1991
Residency: The Cambridge Hospital, Psychiatry, 1991 - 1994
Fellowship: Columbia University Medical Center, Schizophrenia Research, 1999-2002
Board Certifications: American Board of Psychiatry and Neurology, certified and re-certified.
• schizophrenia in its early stages
• cognitive neuroscience
• brain stimulation
NYS Psychiatric Institute
Room 5805 Unit/Box:
1051 Riverside Drive
New York, NY 10032
Phone: 646 774 5238
Dr. Corcoran is interested in characterizing early stages of schizophrenia, including biomarkers, such that early intervention strategies can be developed and implemented.
1. Kayser J, Tenke CE, Kroppmann CJ, Alschuler DM, Ben-David S, Fekri S, Bruder GE, Corcoran C: Olfaction in the Psychosis Prodrome: Electrophysiological and Behavioral Measures of Odor Detection.
. International Journal of Psychophysiology 2013
2. Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, Inbar BP, Corcoran CM, Lieberman JA, Moore H, Small SA.: Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.. Neuron 2013;78: 81-93
3. Corcoran CM, Kimhy D, Parrilla-Escobar MA, Cressman VL, Stanford AD, Thompson J, David SB, Crumbley A, Schobel S, Moore H, Malaspina D.: The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis.. Psychological Medicine 2011;41: 251-261
4. Corcoran CM, First MB, Cornblatt B.: The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis.. Schizophrenia Research 2010;120: 16-22
5. Corcoran C, Whitaker A, Coleman E, Fried J, Feldman J, Goudsmit N, Malaspina D.: Olfactory deficits, cognition and negative symptoms in early onset psychosis.. Schizophrenia Research 2005;80: 283-293